The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Dengue Tetravalent Vaccine (Live, Attenuated) Takeda



Takeda GmbH EU/1/22/1699/002

Main Information

Trade NameDengue Tetravalent Vaccine (Live, Attenuated) Takeda
Active SubstancesDengue virus serotype 1# (live, attenuated)
Dengue virus, serotype 2, live, attenuated
Dengue virus serotype 3# (live, attenuated)
Dengue virus serotype 4# (live, attenuated)
Dosage FormPowder and solvent for solution for injection
Licence HolderTakeda GmbH
Licence Number EU/1/22/1699/002

Group Information

ATC CodeJ07BX04 Dengue virus vaccine

Status

License statusAuthorised
Licence Issued05/12/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsNo document available
Package LeafletNo document available
Public Assessment ReportNo document available
« Back